Cancer / Immunology

GenFleet Therapeutics Collaborates with BeiGene for Advanced Lymphoma Trial

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced it has entered into ...

 March 29, 2024 | News

Bridge Biotherapeutics Partners with University of Colorado for Cancer Research

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a...

 March 27, 2024 | News

Lunit Reveals Positive Study Results for Head and Neck Cancer Immunotherapy

Lunit, a global leader in AI-driven cancer diagnostics and therapy solutions, is thrilled to share the publication of a groundbreaking study in the prestig...

 March 27, 2024 | News

DigmBio's Breakthrough Cancer Drug Clears Korean Regulatory Hurdle

BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breas...

 March 26, 2024 | News

Bayer AG Partners with Thermo Fisher for Breakthrough in Cancer Treatment Diagnostics

Development of next-generation sequencing companion diagnostics (CDx) Goal is to help increase patient access to Bayer’s precision cancer therapie...

 March 20, 2024 | News

CStone's Sugemalimab Granted Historic Approval in China for Gastric Cancer Treatment

CStone Pharmaceuticals has achieved a significant milestone with the approval of sugemalimab (Cejemly®) by the National Medical Products Administration...

 March 18, 2024 | News

BeiGene's TEVIMBRA Wins FDA Nod for Advanced Esophageal Cancer Post-Chemotherapy

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has app...

 March 15, 2024 | News

TiumBio Advances TU2218 in Phase 2a Trial with Pembrolizumab for Three Cancer Types

TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab TU2218 demonstrated a favorable safety and a synerget...

 March 12, 2024 | News

TransThera Launches Global Phase 3 Trial for Cholangiocarcinoma in EU, Receives Orphan Drug Status for Tinengotinib from EMA

TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced that the randomized, controll...

 March 11, 2024 | News

Naveris Inc. Launches Pioneering NAVigate-HPV Registry to Enhance HPV Cancer Diagnostics

-Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of the NAVigate-HPV Registry. This innov...

 March 04, 2024 | News

Enveric Biosciences Divests Cancer-Targeting Cannabinoid IP to Focus on Mental Health Therapeutics

  Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm at the forefront of developing neuroplastogenic small-molecule therapeutics, an...

 February 26, 2024 | News

Cure Brain Cancer Foundation CEO Lance Kawaguchi Triumphs in SouthPoleTrek4Cancer, Raising Over $1 Million

     Lance Kawaguchi, the dynamic CEO of Cure Brain Cancer Foundation, has achieved an extraordinary milestone by ...

 February 26, 2024 | News

BD Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a strategic partnership with Camtech Health, a ...

 February 22, 2024 | News

Japan Accelerates Approval Process for Groundbreaking Urothelial Cancer Treatment by Astellas

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas")  announced that Japan's Ministry of Health, Labour a...

 February 19, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close